A method of selectively inhibiting pathogenic microbes includes: providing an antimicrobial compound that is functional having a structure of Formula 1, or derivative thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combination thereof; and contacting a microbe with the compound such that the microbe is selectively inhibited;
A method of selectively inhibiting pathogenic microbes includes: providing an antimicrobial compound that is functional having a structure of Formula 1, or derivative thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combination thereof; and contacting a microbe with the compound such that the microbe is selectively inhibited;
C07D 209/30 - IndolesHydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
A01N 43/38 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings condensed with carbocyclic rings
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
C07D 209/10 - IndolesHydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
C07D 209/12 - Radicals substituted by oxygen atoms
C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
C07D 209/18 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 209/36 - Oxygen atoms in position 3, e.g. adrenochrome
C07D 209/40 - Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
C07D 209/42 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The Board of Regents of the University of Oklahoma (USA)
Inventor
Singhal, Anuj
Cichewicz, Robert N.
Du, Lin
You, Jianlan
Paritala, Hanumantha Rao
Edwards, Abigail Grace
Wang, Wentian
Abstract
A method of selectively inhibiting pathogenic microbes includes: providing an antimicrobial compound that is functional having a structure of Formula 1, or derivative thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combination thereof; and contacting a microbe with the compound such that the microbe is selectively inhibited;
A method of selectively inhibiting pathogenic microbes includes: providing an antimicrobial compound that is functional having a structure of Formula 1, or derivative thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combination thereof; and contacting a microbe with the compound such that the microbe is selectively inhibited;
C07D 209/30 - IndolesHydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
A01N 43/38 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings condensed with carbocyclic rings
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
C07D 209/10 - IndolesHydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
C07D 209/12 - Radicals substituted by oxygen atoms
C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
C07D 209/18 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 209/36 - Oxygen atoms in position 3, e.g. adrenochrome
C07D 209/40 - Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
C07D 209/42 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A method of differentiating cells can include: providing the in vitro OC device of one of the embodiments; introducing first human mesenchymal stem cell into the cartilage chamber; introducing a chondrogenic differentiation medium into the cartilage chamber with the first human mesenchymal stem cells; incubating the first human mesenchymal stem cells with the chondrogenic differentiation medium sufficiently to differentiate into at least one of chondrocyte cells, chondroblast cells, and/or chondroclast cells; incubating second human mesenchymal stem cells with osteogenic differentiation medium sufficiently to differentiate into at least one of osteoblast cells, osteoclast cells, and/or osteocyte cells; introducing the differentiated at least one of osteoblast cells, osteoclast cells, and/or osteocyte cells into the bone chamber; and introducing vascular endothelial cells into the vasculature chamber.
A microfluidic separation system may include an inlet configured to receive a carrier fluid including first particles. A carrier fluid sorter may be coupled to the inlet. The carrier fluid sorter may include a microfluidic network having a sorter constricted region with a first cross-sectional dimension and a sorter expansion region with a larger second cross-sectional dimension. At least one sorter side channel may be formed into a side of the sorter expansion region to receive a first fraction of the carrier fluid that may be first particle poor. At least one sorter outlet may be positioned downstream or medial from the sorter side channel to receive a second fraction of the carrier fluid that may be first particle concentrated. The microfluidic may be configured to direct the first fraction to the sorter side channel and the second fraction to the sorter outlet.
A system for analyzing a sample can include a sample tube with an input end having a removable lid and an output end, and a microfluidic device. The microfluidic device may include a port member configured to couple with the output end; a sample distribution member coupled with the port member and having a microfluidic network with microfluidic channels; reaction chambers fluidly coupled with the microfluidic channels; and a reactor member configured to generate and display light signals on a display, the light signals generated based on reactions in the reaction chambers and indicating results of the reactions.
In accordance with the purpose(s) of the disclosure, as embodied and broadly described herein, the disclosure, in an aspect, relates to the treatment of a disorder of uncontrolled cellular proliferation in a mammal comprising the step of administering to the mammal a therapeutically effective amount of astemizole and an anticancer agent. In one aspect, the methods described herein inhibiting ANGPTL4 activity in a mammal. In another aspect, the methods described herein inhibit metastasis in a mammal
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
7.
PH-RESPONSIVE ASTEMIZOLE NANOPARTICLES AND METHODS FOR MAKING AND USING THE SAME
In accordance with the purpose(s) of the disclosure, as embodied and broadly described herein, the disclosure, in an aspect, relates to pH-responsive nanoparticles described herein facilitate the release of astemizole to effectively release astemizole locally, preventing or reducing cancer cell growth, while minimizing effects on healthy cells. The compositions comprise a pH-responsive nanoparticle having a core comprising astemizole or a pharmaceutically acceptable salt thereof encapsulated by a pH-responsive polymer carrier. The pH-responsive nanoparticles can be administred alone or in combination with other other pharmaceutical compounds such as, for example, anticancer agent.
A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
C08L 53/00 - Compositions of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bondsCompositions of derivatives of such polymers
A diagnostic system is provided, which can include a sample tube having an input end and an output end, a microfluidic device, a heating member, and a reagent. The microfluidic device may include a port member configured to couple with the sample tube, a sample distribution member coupled with the port member and having a microfluidic network with microfluidic channels, reaction chambers fluidly coupled with the microfluidic channels, a top cover configured to receive the sample tube therein and having openings corresponding to the reaction chambers, and a bottom member configured to mate with the top cover to enclose the port member and the sample distribution member. The bottom member may include a bottom chamber for retaining a composition. The heating member may be placed in the bottom chamber, and the reagent in the reaction chambers may provide a colorimetric reading upon interaction with a target analyte in the sample.
A method of performing an asymmetric loop-mediated isothermal amplification (LAMP) assay can include: providing the asymmetrical primer set of one of the embodiments; providing a reagent composition having a polymerase; combining the asymmetrical primer set and reagent composition with a sample having the target nucleic acid to form an amplification mixture; heating the amplification mixture to an amplification temperature within an amplification temperature range; maintaining the amplification temperature to amplify the target nucleic acid having the target sequence; and obtaining an amplified amount of the target nucleic acid having the target sequence. The asymmetrical primer set can include one primer of a primer pair to be at a lower (e.g., 10%) amount of the other primer.
A method of power generation is provided that uses one or more structures made of zirconium tungstate in a convection fluid that rise or fall with temperature to create a reverse convection current cycle. The method can include heating the one or more zirconium tungstate structures to cause a decrease in volume and sink in the convection fluid. The method can include cooling the one or more zirconium tungstate structures to cause an increase in volume and rise in the convection fluid. The method includes generating power from the reverse convection current cycle.
A microfluidic in vitro cornea device is provided, which can include a tear flow chamber, stromal chamber, endothelial chamber, and aqueous humor chamber. The stromal chamber is adjacent to and porously coupled with the tear flow chamber. The endothelial chamber is adjacent to and porously coupled with the stromal chamber. The aqueous humor chamber adjacent to and porously coupled with the endothelial chamber. A first porous wall is positioned between the tear flow chamber and the stromal chamber. A second porous wall is positioned between the stromal chamber and the endothelial chamber. The third porous wall is positioned between the endothelial chamber and the aqueous humor chamber. The device is configured as a microfluidic in vitro model of a cornea.
The method involves computationally modeling a cornea by simulating physical cornea models with computational in silico models. The simulated data is compared with actual data from the physical models, and the simulation is iterated until a match is achieved. The method may also include calibrating diffusion parameters for testing substances, and configuring the models for analyzing instances of fluid-induced shear and substance transport. The simulated data may be used to obtain corneal pharmacokinetic models, and the method may be used to obtain predictions for time-dependent concentrations of molecules in the eye or systemic circulation. The computational models may consider instances of convective-diffusive transport and carrier-mediated transport in calculations and determinations of transport characteristics and values of different testing substances.
G06T 15/00 - 3D [Three Dimensional] image rendering
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
13.
COMPUTATIONAL IN SILICO MODEL FOR PLACENTAL BARRIER
The method involves computationally modeling a placenta by simulating physical placenta models with computational in silico models. The simulated data is compared with actual data from the physical models, and the simulation is iterated until a match is achieved. The method may also include calibrating diffusion parameters for testing substances, and configuring the models for analyzing instances of fluid-induced shear and substance transport. The simulated data may be used to obtain maternal-fetal pharmacokinetic in silico placenta models, and the method may be used to obtain predictions for time-dependent concentrations of molecules in fetal circulation. The computational models may consider instances of fluid-diffusive transport and carrier-mediated transport in calculations and determinations of transport characteristics and values of different testing substances.
The method involves computationally modeling a placenta by simulating physical placenta models with computational in silico models. The simulated data is compared with actual data from the physical models, and the simulation is iterated until a match is achieved. The method may also include calibrating diffusion parameters for testing substances, and configuring the models for analyzing instances of fluid-induced shear and substance transport. The simulated data may be used to obtain maternal-fetal pharmacokinetic in silico placenta models, and the method may be used to obtain predictions for time-dependent concentrations of molecules in fetal circulation. The computational models may consider instances of fluid-diffusive transport and carrier-mediated transport in calculations and determinations of transport characteristics and values of different testing substances.
The present disclosure relates to articles that are therapeutic coverings and wraps comprising a substrate and a releasable therapeutic agent in contact with or attached to one another. The articles comprising therapeutic coverings and wraps are useful for treatment of atopic dermatitis and/or are useful for treatment of wounds. The substrate can comprise a textile having hydroxyl groups in the textile yarn or filament such as cotton, rayon, silk, or combinations thereof. The therapeutic agent interacts with or is attached to the substrate via non-covalanet interactions, or alternatively via a covalent linkage that can release the therapeutic agent. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
A61L 15/20 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
A state of battery testing system is disclosed which includes a charger, a load to be coupled across the battery's positive and negative terminals, a processer adapted to apply a predetermined voltage pulse across the battery's positive and negative terminals, apply the load to the battery, measure and log current through the load as Iexp, and establish a model based on establishing an initial estimation of state of the battery (θ0), and establishing a modeled state of battery (θi) based on a plurality of internal parameters of the battery. The model is adapted to output a model current through the load, inputting θ0 and the plurality of internal parameters of the model to thereby generate Imodel, generate an objective function (f) based on a comparison of Imodel and Iexp, and iteratively optimize θi, and output θoptimal based on the iterations.
G01R 31/36 - Arrangements for testing, measuring or monitoring the electrical condition of accumulators or electric batteries, e.g. capacity or state of charge [SoC]
G01R 31/367 - Software therefor, e.g. for battery testing using modelling or look-up tables
G01R 31/3842 - Arrangements for monitoring battery or accumulator variables, e.g. SoC combining voltage and current measurements
G01R 31/392 - Determining battery ageing or deterioration, e.g. state of health
17.
SELF-ENCLOSED BIOREACTOR FOR VASCULARIZED TISSUE CONSTRUCTS
A bioreactor can include: a tissue culture chamber; at least one inlet port into the tissue culture chamber; an inlet port member located in each inlet including an inlet tube extending into the tissue culture chamber; at least one outlet port into the tissue culture chamber; an outlet port member located in each outlet including an outlet tube extending into the tissue culture chamber; an optical cover; and a hydrogel can be located in the tissue culture chamber having at least one lumen fluidly coupling the inlet tube to the outlet tube, wherein an inlet interface region of the hydrogel is constrained around the inlet tube and an outlet interface region of the hydrogel is constrained around the outlet tube.
The present invention includes systems and methods for providing cybersecurity to web-enabled applications for protection of critical software and host systems. The present invention is operable to build a Hidden Markov model of an application using automated analysis of code and documentation in order to characterize potential state and state transitions. The present invention is also operable to use additional data such as timing and proximity to assess incoming data. Incoming messages are then assigned a trust score based on Bayesian calculations.
A method for nitrous decomposition can include: expanding liquid nitrous into gaseous nitrous in a decomposition chamber; injecting heated nitrogen gas into the decomposition chamber so as to mix with the gaseous nitrous, wherein the heated nitrogen gas is at a nitrous decomposition temperature; heating the gaseous nitrous with the heated nitrogen gas to the nitrous decomposition temperature; and decomposing the gaseous nitrous into nitrogen and oxygen. The method can include: heating the nitrogen to at least the nitrous decomposition temperature; heating the liquid nitrous prior to expansion into the decomposition chamber; and performing the decomposition without a catalyst or heating element in the decomposition chamber. A swirling device can be positioned at an inlet to the decomposition chamber. A swirling nozzle can be positioned at an inlet to the decomposition chamber.
A variable 3D CD nozzle includes: a flexible body defining a flow path having an inlet extending through a narrowed throat to an expanded outlet, wherein the flexible body comprises a plurality of flexible members movably interconnected together; and at least one means for changing a shape of the flexible body to change a dimension or location of the throat plane relative to at least one of the inlet plane or outlet plane. A method of changing airflow in a nozzle includes operating at least one means for changing the shape of the flexible nozzle body to change the dimension or the location of the throat plane. A method of testing an object includes placing a test object in the test region of the test cell and passing a test gas from the outlet opening of the nozzle onto the test object.
A method of producing electrical power includes: a cathode having a porphyrin precursor attached to a substrate, and having a first enzyme, wherein the first enzyme reduces oxygen; an anode having a first region of an anode substrate and having a gold nanoparticle composition located thereon, and having a second region of the anode substrate having an enzyme composition located thereon, wherein the enzyme composition includes a second enzyme, wherein the first region and second region are separate regions; and a neutral fuel liquid in contact with the anode and cathode, the neutral fuel liquid having a neutral pH and a fuel reagent; and operating the fuel cell to produce electrical power with the neutral fuel liquid having the neutral pH and the fuel reagent.
A portable platelet apheresis system can include: a whole blood inlet configured to receive whole blood; an anticoagulant source containing an anticoagulant; a mixer fluidly coupled with the whole blood inlet and anticoagulant source and configured to mix the whole blood and the anticoagulant; a whole blood sorter microfluidic network; a platelet poor outlet positioned to receive a platelet poor fraction; and a platelet concentrator outlet positioned to receive a concentrated platelet fraction. The whole blood sorter microfluidic network includes: a sorter constricted region having a first cross-sectional dimension; a sorter expansion region having a second cross-sectional dimension that is larger than the first cross-sectional dimension; at least one sorter side channel (platelet rich plasma channel) formed into a side of the sorter expansion region; and at least one sorter outlet (platelet poor plasma channel) that is downstream or medial from the at least one sorter side channel.
A method for providing a therapy to a subject that has been exposed to an Aflatoxin B1 can include administering a compound having a structure of Formula 1 to the subject after exposure to the Aflatoxin B1:
6 are each individually a chemical moiety and n is 1, 2, 3, 4, or 5. The compound can be Amprenavir or a derivative thereof, prodrug thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combination thereof. The prodrug can be Amprenavir phosphate.
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A61K 31/665 - Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
24.
Non-lethal weapons modular human surrogate testing device and method
A modular surrogate can include: a body having an external body surface with an anatomical shape, wherein the body includes an internal chamber with at least one port formed in the body extending inwardly; at least one anatomical module having an external module portion and a module stem coupled thereto, the module stem being received into a corresponding module port of the at least one port, the external module portion having an external module surface with an anatomical shape, the external body surface matches with the external module surface to provide a continuous anatomical shape; at least one sensor located in the at least one anatomical module; and at least one controller, wherein when the at least one anatomical module is coupled with the body, the at least one sensor is capable of being operably coupled with the at least one controller.
In an aspect, the disclosure pertains to inhibitors of ANGPTL4; synthesis methods for making disclosed compounds; pharmaceutical compositions comprising disclosed compounds; methods of treating disorders of uncontrolled cellular proliferation, e.g., a cancer; and methods of treating a disease associated with an ANGPTL4 dysfunction using disclosed compounds and pharmaceutical compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07J 31/00 - Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
C07C 59/72 - Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
A61P 35/04 - Antineoplastic agents specific for metastasis
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
26.
Device and method for breaching outward opening and reinforced doors
A door breach device can include: an elongate shaft having a first end and an opposite second end; a pivot mechanism at the first end of the shaft; a spearhead rotatably coupled with the pivot mechanism and having a tip on a tip-side of the pivot mechanism and having a shaft cavity on a shaft-side, where the shaft cavity is adapted to receive the shaft therein; a restraint slidably received on the shaft-side of the spearhead and on the shaft; a handle protruding from the shaft; and a hitch at the second end of the shaft. A method of breaching a door can include: forcing the spearhead through a door until the restraint releases the spearhead and the spearhead rotates by the pivot mechanism so as to form an angle with the shaft; and pulling the spearhead against the door until the door is breached.
B25D 9/00 - Portable percussive tools with fluid-pressure drive, e.g. having several percussive tool bits operated simultaneously
A62B 3/00 - Devices or single parts for facilitating escape from buildings or the like, e.g. protection shields, protection screensPortable devices for preventing smoke penetrating into distinct parts of buildings
A fluidic device can include: a plurality of fluid conduits, each fluid conduit including a first conduit portion separated from a second conduit portion; and at least one transport body that is movably positioned between the first conduit portion and the second conduit portion of each fluid conduit. The at least one transport body can include: at least one port adapted to be aligned with a first conduit portion and a second conduit portion of at least one first conduit so as to fluidly couple the first conduit portion with the second conduit portion; and at least one blocking body portion adapted to be aligned with a first conduit portion and a second conduit portion of at least one second conduit so as to fluidly isolate the first conduit portion from the second conduit portion of the at least one second conduit.
The Board of Regents of the University of Oklahoma (USA)
Inventor
Singhal, Anuj
Cichewicz, Robert H.
Du, Lin
You, Jianlan
Paritala, Hanumantha Rao
Edwards, Abigail Grace
Abstract
A method of selectively inhibiting pathogenic microbes includes: providing a compound that is functional as a selective antimicrobial having a structure of Formula 1, or derivative thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combination thereof; and contacting a pathogenic microbe with the compound such that the pathogenic microbe is selectively inhibited;
4 is independently a substituent; m is 0, 1, 2, 3, or 4; and n is zero or a positive integer.
C07D 209/30 - IndolesHydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A01N 43/38 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings condensed with carbocyclic rings
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A01N 55/00 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A01N 25/08 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing solids as carriers or diluents
29.
Antimicrobial compounds, compositions, and articles of manufacture for selectively inhibiting pathogenic microbes
The Board of Regents of the University of Oklahoma (USA)
Inventor
Singhal, Anuj
Cichewicz, Robert H.
Du, Lin
You, Jianlan
Paritala, Hanumantha Rao
Edwards, Abigail Grace
Abstract
A compound can have a structure of Formula A, or derivative thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combination thereof:
3 is a substituent other than a hydrogen; m is 0, 1, 2, 3, or 4; and n is 0 or a positive integer. The compounds can have specific substituent patterns.
C07D 209/30 - IndolesHydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
A01N 25/08 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing solids as carriers or diluents
A01N 43/38 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings condensed with carbocyclic rings
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
A01N 55/00 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The Government of The United States, as represented by the Secretary of the Army (USA)
Inventor
Przekwas, Andrzej
Garimella, Harsha T.
Zehnbauer, Timothy
Chen, Zhijian
Harrand, Vincent
Gupta, Raj Kumar
Kamimori, Gary
Carr, Walter
Abstract
A method of calculating blast injury metrics in a weapon training/IED blast scene can include: reconstructing topological layout of the scene having at least one real subject and a blast source; obtaining anthropometric and posture data for each real subject; obtaining anatomical soldier model for each real subject; identifying real position of at least one real pressure sensor on each soldier during a blast; positioning a virtual sensor on each anatomical soldier model to correspond with real pressure sensor on the real subject; calculating weapon signature of the blast source, the weapon signature including pressure versus time for a blast from the blast source; generating simulated pressure traces on each anatomical soldier model at east virtual pressure sensor; calculating blast injury metrics for the at least one real subject; and generating a report that includes the blast injury metrics for the at least one real subject.
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G01L 5/00 - Apparatus for, or methods of, measuring force, work, mechanical power, or torque, specially adapted for specific purposes
G01L 5/14 - Apparatus for, or methods of, measuring force, work, mechanical power, or torque, specially adapted for specific purposes for measuring the force of explosionsApparatus for, or methods of, measuring force, work, mechanical power, or torque, specially adapted for specific purposes for measuring the energy of projectiles
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
31.
System and method for reconstruction of explosion blast and blast loading on humans using pressure sensor data
The Government of the United States, as represented by the Secretary of the Army (USA)
Inventor
Chen, Zhijian
Przekwas, Andrzej
Harrand, Vincent
Gupta, Raj K.
Abstract
A system for reconstruction of an explosion blast loading on a subject can include at least two pressure sensors and a computing system configured to: receive sensor data from the at least two pressure sensors, the sensor data being generated in response to an explosion blast wave; compute an explosion location and explosive charge mass of an explosive that caused the explosion blast wave based on the sensor data; and compute explosion blast loading on a subject from the explosion location and explosive charge mass. The pressure sensors can be configured as wearable pressure sensors or on equipment. The computing of the explosion location and explosive charge mass includes processing the sensor data through an inverse problem solver (IPS); and/or the computing of the explosion blast loading on the subject includes simulating the explosion blast wave with a forward problem solver (FPS).
G01L 5/00 - Apparatus for, or methods of, measuring force, work, mechanical power, or torque, specially adapted for specific purposes
G01L 5/14 - Apparatus for, or methods of, measuring force, work, mechanical power, or torque, specially adapted for specific purposes for measuring the force of explosionsApparatus for, or methods of, measuring force, work, mechanical power, or torque, specially adapted for specific purposes for measuring the energy of projectiles
G01N 3/313 - Investigating strength properties of solid materials by application of mechanical stress by applying a single impulsive force generated by explosives
A cathode can include: an electrode substrate; a porphyrin precursor attached to the substrate; and an enzyme coupled to the electrode substrate to be associated with the porphyrin precursor, the enzyme reduces oxygen. The cathode can include a conductive material associated with the porphyrin precursor and/or the enzyme. The cathode can include 1-pyrenebutanoic acid, succinimidyl ester (PBSE) associated with the porphyrin precursor and/or the enzyme and/or the conductive material. The cathode can include 2,5-dimethyl-1-phenyl-1H-pyrrole-3-carbaldehyde (DMY-Carb) associated with the 1-pyrenebutanoic acid, succinimidyl ester (PBSE) and/or the porphyrin precursor and/or the enzyme and/or the conductive material. The porphyrin precursor is attached to the substrate through covalent coupling. In some aspects, substrate is linked to the porphyrin precursor, the porphyrin precursor is linked to the conductive material, the conductive material is linked to the PBSE, the PBSE is linked to the DMY-carb, and the DMY-carb is linked to the enzyme.
2, MnO, zeolite, alumina, graphitic carbon, palladium, platinum, gold, ruthenium, rhodium, iridium, or combinations thereof. The catalyst can be nanoparticle, nanorod, nanodot, or combination thereof. The catalyst can have sizes that range from about 10 to 20 nm.
A passive non-linear earplug can include: a tapered body having a channel extending from a wider distal end to a narrower proximal end, the tapered body having shape memory and size adapted for being received into an ear canal of a human subject; and a disk attached to the wider distal end of the tapered body, the disk having one or more holes aligned with the channel. A structural tube can be located in the channel. A handle can be attached to the tapered body and/or disk. An annular member can be coupled to the disk opposite of the tapered body, the annular member having an aperture that at least partially aligns with the channel. A tube member can be coupled to the disk opposite of the tapered body. The earplug can attenuate loud sounds while allowing normal sounds to be heard, which provides for the non-linearity.
H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
The present disclosure generally pertains to a rocket propulsion oxidizer compound that is a solution, is a homogenous and stable liquid at room temperature and includes nitrous oxide and nitrogen tetroxide. In addition, an apparatus is provided for burning a fuel and nitrous oxide/nitrogen tetroxide. The apparatus has a combustor, a catalyst, a nitrous oxide/nitrogen tetroxide supply passage for directing the nitrous oxide/nitrogen tetroxide to a contact position with the catalyst, and a fuel supply passage for supplying the fuel to the combustor. The catalyst acts to facilitate decomposition of the nitrous oxide/nitrogen tetroxide, while the combustor burns the fuel, the decomposed nitrous oxide/nitrogen tetroxide and/or nitrous oxide/nitrogen tetroxide decomposed in the reaction.
C06B 47/00 - Compositions in which the components are separately stored until the moment of burning or explosion, e.g. "Sprengel"-type explosivesSuspensions of solid component in a normally non-explosive liquid phase, including a thickened aqueous phase
C06B 47/04 - Compositions in which the components are separately stored until the moment of burning or explosion, e.g. "Sprengel"-type explosivesSuspensions of solid component in a normally non-explosive liquid phase, including a thickened aqueous phase the components comprising a binary propellant a component containing a nitrogen oxide or acid thereof
D03D 23/00 - General weaving methods not special to the production of any particular woven fabric or the use of any particular loomWeaves not provided for in any other single group
C06B 43/00 - Compositions characterised by explosive or thermic constituents not provided for in groups
F02K 9/42 - Rocket-engine plants, i.e. plants carrying both fuel and oxidant thereforControl thereof using liquid or gaseous propellants
C06B 33/08 - Compositions containing particulate metal, alloy, boron, silicon, selenium or tellurium with at least one oxygen supplying material which is either a metal oxide or a salt, organic or inorganic, capable of yielding a metal oxide with a nitrated organic compound
Disclosed herein are media for culture of cells, tissues, and/or organs. The media formulations disclosed herein can be used to support growth, viability, and/or function of one or more than one cell type, tissue, or organ. In some embodiments, one or more cell types, tissues, organ devices, and/or organs are contacted with a disclosed culture medium under conditions sufficient to support growth, viability, and/or function of the cell types, tissues, and/or organs. The disclosed media can be used in methods of culturing multiple cell types, and in some examples, is used in a platform device including one or more organ devices, for example, by circulating the medium through the one or more organ devices in the platform.
4. A thermal battery can include the electrolyte composition, such as in the cathode, anode, and/or separator region therebetween. The battery can discharge electricity by having the electrolyte composition at a temperature so as to be a molten electrolyte.
H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
The present disclosure provides a method of generating electricity from a long chain hydrocarbon, said method comprising contacting the liquid non-polar substrate with a plurality of enzymes, wherein at least one enzyme is non-electric current/potential enzyme that functions as a catalyst for chemical reaction transforming a first substrate or byproduct to a second substance that can be used with an additional electric current/potential generating enzyme.
An analyte selection device can include: a body defining a fluid channel having a channel inlet and channel outlet; a bipolar electrode (BPE) between the inlet and outlet; one of an anode or cathode electrically coupled with the BPE on a channel inlet side of the BPE and the other of the anode or cathode electrically coupled with the BPE on a channel outlet side of the BPE; and an electronic system operably coupled with the anode and cathode so as to polarize the BPE. The fluid channel can have any shape or dimension. The channel inlet and channel outlet can be longitudinal or lateral with respect to the longitudinal axis of the channel. The BPE can be any metallic member, such as a flat plate on a wall or mesh as a barrier BPE. The anode and cathode can be located at a position that polarizes the BPE.
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
G01N 15/02 - Investigating particle size or size distribution
G01N 30/00 - Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography
A cell culture assay device can include: a substrate having a plurality of discrete microfluidic networks and a plurality of wells over the discrete microfluidic networks, each discrete microfluidic network having one or more wells fluidly coupled thereto, the wells extending upward from the discrete microfluidic networks; and a manifold body coupled with the substrate and having at least one fluid conduit pair for each microfluidic network and/or each well, each fluid conduit pair including a fluid inlet conduit and a fluid outlet conduit fluidly coupled to a corresponding microfluidic network and/or well. The substrate can be formed from a substrate base having the microfluidic networks coupled to a well plate having the wells associated with the microfluidic networks.
A cell culture device can include: a top wall; a bottom wall; one or more perimeter walls coupled with and extending between the top wall and bottom wall; and at least 3 distinct chambers between the top wall, bottom wall. The one or more perimeter walls can include: an internal chamber defined by at least one porous internal wall and having an internal chamber inlet and an internal chamber outlet; one or more boundary layer chambers having at least an inner boundary layer chamber defined by the at least one porous internal wall and at least one porous inner boundary layer wall, the at least one porous internal wall having a plurality of pores fluidically coupling the central internal chamber to the one or more boundary layer chamber; and an outer chamber defined by an outer porous boundary layer wall of the at least one porous boundary layer walls and the one or more perimeter walls and having an outer chamber inlet and an outer chamber outlet, the outer porous boundary layer wall having a plurality of pores that fluidically couple the outer chamber with the one or more boundary layer chambers. In one aspect, wherein the at least three distinct chambers are nonlinear and/or idealized.
An apparatus for concentrating aerosol particles can include: a sample air inlet; an enriched aerosol outlet; an aerosol lean outlet; a flow path connecting the air inlet and aerosol rich and aerosol lean outlets; and a plurality of alternately energized and grounded electrode pairs along the flow path. The aerosol rich outlet can be in fluid communication with an aerosol particle capture device. The apparatus can include a sheath air inlet providing a flow of aerosol free air over surfaces of the alternately energized and grounded electrode pairs. The apparatus can include an elongate focusing chamber having a cylindrical shape containing the alternately energized and grounded electrode pairs that are configured as circular rings. The apparatus can include one or more structures configured to impart tangential, spiral or helical flow to a stream entering through the sample air inlet.
A group of tertiary amine azides are useful as hypergolic fuels for hypergolic bipropellant mixtures. The fuels provide higher density impulses than monomethyl hydrazine (MMH) but are less toxic and have lower vapor pressures that MMH. In addition, the fuels have shorter ignition delay times than dimethylaminoethylazide (DMAZ) and other potential reduced toxicity replacements for MMH.
C06B 47/00 - Compositions in which the components are separately stored until the moment of burning or explosion, e.g. "Sprengel"-type explosivesSuspensions of solid component in a normally non-explosive liquid phase, including a thickened aqueous phase
C06B 25/34 - Compositions containing a nitrated organic compound the compound being a nitrated acyclic, alicyclic or heterocyclic amine
D03D 23/00 - General weaving methods not special to the production of any particular woven fabric or the use of any particular loomWeaves not provided for in any other single group
Particle separation apparatus separate particles and particle populations using dielectrophoretic (DEP) forces generated by one or more pairs of electrically coupled electrodes separated by a gap. Particles suspended in a fluid are separated by DEP forces generated by the at least one electrode pair at the gap as they travel over a separation zone comprising the electrode pair. Selected particles are deflected relative to the flow of incoming particles by DEP forces that are affected by controlling applied potential, gap width, and the angle linear gaps with respect to fluid flow. The gap between an electrode pair may be a single, linear gap of constant gap, a single linear gap having variable width, or a be in the form of two or more linear gaps having constant or variable gap width having different angles with respect to one another and to the flow.
The present disclosure provides an electrode including an electrically conductive ink deposited thereon comprising: a nano-scale conducting material; a binding agent; and an enzyme; wherein said ink is essentially solvent free. In one embodiment, the ink includes at least one of a mediator, a cross-linking agent and a substrate as well. In one further embodiment, the electrode provided herein is used in a battery, fuel cell or sensor.
H01B 1/00 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors
H01B 1/04 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of carbon-silicon compounds, carbon, or silicon
H01B 1/06 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances
The present disclosure provides an aqueous based electrically conductive ink, which is essentially solvent free and includes a nano-scale conducting material; a binding agent; and an enzyme. In one embodiment, the ink includes at least one of a mediator, a cross-linking agent and a substrate as well. In one further embodiment, the present disclosure provides electrically conductive ink including a single walled, carboxylic acid functionalized carbon nanotube; 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride and N-hydroxy succinimide (NHS) ester; polyethyleneimine; an aqueous buffer; and glucose oxidase.
H01B 1/00 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors
H01B 1/04 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of carbon-silicon compounds, carbon, or silicon
H01B 1/06 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances
A group of tertiary amine azides are useful as hypergolic fuels for hypergolic bipropellant mixtures. The fuels provide higher density impulses than monomethyl hydrazine (MMH) but are less toxic and have lower vapor pressures that MMH. In addition, the fuels have shorter ignition delay times than dimethylaminoethylazide (DMAZ) and other potential reduced toxicity replacements for MMH.
C06B 47/00 - Compositions in which the components are separately stored until the moment of burning or explosion, e.g. "Sprengel"-type explosivesSuspensions of solid component in a normally non-explosive liquid phase, including a thickened aqueous phase
C06B 25/34 - Compositions containing a nitrated organic compound the compound being a nitrated acyclic, alicyclic or heterocyclic amine
D03D 23/00 - General weaving methods not special to the production of any particular woven fabric or the use of any particular loomWeaves not provided for in any other single group
A method for preparing a gelled liquid propane (GLP) composition comprises the introduction of liquid propane into an evacuated mixing vessel containing a gellant and mixing the liquid propane with the gellant. A bi-propellant system comprising GLP is particularly well-suited for outer planet missions greater than 3 AU from the sun and also functions in earth and near earth environments. Additives such as powders of boron, carbon, lithium, and/or aluminum can be added improve performance or enhance hypergolicity. The gelling agent can be silicon dioxide, clay, carbon, or organic or inorganic polymers. The bi-propellant system may be, but need not be, hypergolic.
An electrostatic aerosol concentrator includes an airflow chamber with alternately energized and grounded electrode elements that work in concert to impart radial inward motion to charged aerosol particles and focusing them toward an enriched aerosol outlet. Aerosol particles entering the airflow chamber may carry a positive or negative charge naturally, or a charge may be induced on the particles using a charging section located upstream of the aerosol inlet. Natural or induced charges on the aerosol particles may be used to selectively concentrate subpopulations of aerosol particles from a mixture of particles. For example, bacterial spores or aerosolized viruses may be selectively enriched without concentrating other aerosol particles.
A microfluidic cartridge for isolating biological molecules having a capture chamber containing functionalized solid supports maintained in a fluidized state provides reduced pressure drops and bubble formation during microfluidic extraction. The cartridge may include an electric field lysis chamber and/or a chemical lysis chamber. The electric-field lysis chamber may comprise an electrically insulating structure arranged between two opposing planar electrodes.
The present invention provides a pseudospark switch that overcomes the aforementioned limitations of existing pseudospark switches and proved e-beams for applications such as FELs, pulsed lasers, X-ray machines, and radar. The improvement in e-beam quality is obtained by inductively ionizing gas inside the hollow cathode chamber (HCC), prior to main gap breakdown using a HCC that incorporates a spiral induction coil. The gas in the hollow cathode chamber is ionized by the discharge of an auxiliary capacitor bank through the spiral coil that forms the back surface of the HCC.
The present invention is a constant volume rocket motor that uses a non-detonating constant-volume, bipropellant combustion process in pulse-mode operation. Opening and closing of the combustion chamber exhaust outlet is controlled by an actuated reciprocating thrust valve (RTV). Fuel enters the combustion chamber at low pressure with the RTV closed. The valve opens after or during combustion when combustion chamber pressure is at or near maximum. The motor has applications in reaction control systems and attitude control systems in spacecraft.
Disclosed is a group of tertiary amine azides useful as hypergolic fuels for hypergolic bipropellant mixtures. The fuels provide higher density impulses than monomethyl hydrazine (MMH) but are less toxic and have lower vapor pressures that MMH. In addition, the fuels have shorter ignition delay times than dimethylaminoethylazide (DMAZ) and other potential reduced toxicity replacements for MMH.
C06B 47/00 - Compositions in which the components are separately stored until the moment of burning or explosion, e.g. "Sprengel"-type explosivesSuspensions of solid component in a normally non-explosive liquid phase, including a thickened aqueous phase
C06B 31/00 - Compositions containing an inorganic nitrogen-oxygen salt
C06B 31/28 - Compositions containing an inorganic nitrogen-oxygen salt the salt being ammonium nitrate
C06B 47/04 - Compositions in which the components are separately stored until the moment of burning or explosion, e.g. "Sprengel"-type explosivesSuspensions of solid component in a normally non-explosive liquid phase, including a thickened aqueous phase the components comprising a binary propellant a component containing a nitrogen oxide or acid thereof
D03D 23/00 - General weaving methods not special to the production of any particular woven fabric or the use of any particular loomWeaves not provided for in any other single group
The present invention is a catalytic chemical vapor deposition method and apparatus for synthesizing carbon nanotubes and/or carbon nanofibers (CNTs) on a substrate by selectively heating a catalyst for CNT synthesis on or near the surface of the substrate. Selective heating of the catalyst is achieved using an exothermic oxidation reaction on the surface of the catalyst, inductive heating from a radio frequency source, or both. Selective heating of the catalyst prevents heating of the substrate and enables the synthesis of CNTs on temperature sensitive substrates.
D01F 9/127 - Carbon filamentsApparatus specially adapted for the manufacture thereof by thermal decomposition of hydrocarbon gases or vapours
B82B 3/00 - Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
56.
Synthesis of carbon nanotubes by selectively heating catalyst
The present invention is a catalytic chemical vapor deposition method and apparatus for synthesizing carbon nanotubes and/or carbon nanofibers (CNTs) on a substrate by selectively heating a catalyst for CNT synthesis on or near the surface of the substrate. Selective heating of the catalyst is achieved using an exothermic oxidation reaction on the surface of the catalyst. Selective heating of the catalyst prevents heating of the substrate and enables the synthesis of CNTs on temperature sensitive substrates.
C23C 16/00 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes
C23C 4/00 - Coating by spraying the coating material in the molten state, e.g. by flame, plasma or electric discharge
The present invention is a constant volume rocket motor that uses a non-detonating constant-volume, bipropellant combustion process in pulse-mode operation. Opening and closing of the combustion chamber exhaust outlet is controlled by an actuated reciprocating thrust valve (RTV). Fuel enters the combustion chamber at low pressure with the RTV closed. The valve opens after or during combustion when combustion chamber pressure is at or near maximum. The motor has applications in reaction control systems and attitude control systems in spacecraft.
F02K 5/02 - Plants including an engine, other than a gas turbine, driving a compressor or a ducted fan the engine being of the reciprocating-piston type
The present invention is a synthetic microfluidic microvasculature network and associated methods. The synthetic microfluidic microvasculature network mimics the structure, fluid flow characteristics, and physiological behavior of physiological microvasculature networks. Computational methods for simulating flow and particle adherence in synthetic and physiological microvascular systems and methods for determining parameters influencing particle adhesion and drug delivery are also described. The invention has many uses including the optimization of drug delivery and microvascular treatments and in describing disease mechanisms that affect the microvasculature such as inflammation, diabetes and hypertension.
The present invention is a method and apparatus for gelling liquid propane and other liquefied gasses. The apparatus includes a temperature controlled churn mixer, vacuum pump, liquefied gas transfer tank, and means for measuring amount of material entering the mixer. The method uses gelling agents such as silicon dioxide, clay, carbon, or organic or inorganic polymers, as well as dopants such as titanium, aluminum, and boron powders. The apparatus and method are particularly useful for the production of high quality rocket fuels and propellants.
The present invention is an electrostatic collector for low cost, high throughput, high efficiency sampling and concentration of bioaerosols. The device is small enough to be portable and can be contained within or placed on the wall of a typical office or hospital building. The collector comprises one or more collector modules, each having an ionizing electrode, a conical outer electrode, a wet collection electrode, and a liquid collection system. Airflow through a collector module may be partially blocked to enhance the collection of smaller particles and the collection electrode may comprise multiple, programmable electrodes to focus particle deposition onto a smaller area. Particles are collected into a small volume of liquid to facilitate subsequent analysis by an attached analyzer or at a remote site.
Methods and apparatus for the micro-scale, dielectrophoretic separation of particles are provided. Fluid suspensions of particles are sorted and separated by dielectrophoretic separation chambers that have at least two consecutive, electrically coupled planar electrodes separated by a gap in a fluid flow channel. The gap distance as well as applied potential can be used to control the dielectrophoretic forces generated. Using consecutive, electrically coupled electrodes rather than electrically coupled opposing electrodes facilitates higher flow volumes and rates. The methods and apparatus can be used, for example, to sort living, damaged, diseased, and/or dead cells and functionalized or ligand-bound polymer beads for subsequent identification and/or analysis.
patents
